Topical pimecrolimus and tacrolimus and the risk of cancer;Pimecrolimus/tacrolimus tópicos y riesgo de cáncer

Actas Dermo-Sifiliograficas

Volumn 98, Issue 5, 2007, Pages 312-317

  Sánchez Pérez, Javier ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Experimental studies; Lymphoma; Melanoma; Nonmelanoma skin cancer; Pimecrolimus; Posttransplant lymphoproliferative disease; Tacrolimus

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; PIMECROLIMUS; RIZAN; TACROLIMUS; UNCLASSIFIED DRUG;

CANCER RISK; CARCINOGENESIS; DRUG INDICATION; EXPERIMENTAL STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; REVIEW; SKIN CANCER; SKIN MANIFESTATION;

EID: 34347366299     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(07)70074-1     Document Type: Article

References (48)

1. Fonseca E. Inhibidores tópicos de la calcineurina. Piel. 2004; 19:4-7.
2. U.S. Food and Drugs Administration. Anonymous: new warnings for two eczema drugs. Disponible en: http://www. fda.gov/fdac/departs/2006/206_upd.html. Consultado 11 de marzo de 2007.
3. European Medicines Agency. Cautious use of protopic/protopy and elidel. Disponible en: http://www.emea.europa.eu/ pdfs/general/direct/pr/9888206en.pdf. Consultado 11 de marzo de 2007.
4. Baselga E. Tratamiento de la dermatitis atópica en la infancia. Actas Dermosifiliogr. 2003;94:345-55.
5. Agencia Española del Medicamentos y Productos sanitarios. Elidel (pimecrolimus) y Protopic (tacrolimus) y riesgos de tumores, 4 de abril del 2005. Disponible en: http://www.age-med.es/actividad/alertas/docs/NI_2005-7.pdf. Consultado 11 de marzo de 2007.
6. Becker JC, Houben R, Vetter CS, Brocker EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer. 2006,11;6:7.
7. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125:1020-5.
8. Food and Drug Administration. Novartis Elidel (pimecrolimus) cream 1 % briefing document, (6/2006). Disponible en: www.fda.gov/cder/foi/label/2006/ 021302s011lbl.pdf. Consultado el 11 de marzo de 2007.
9. Food and Drug Administration. Astellas Pharma (tacrolimus) ointment 0,03 % and 0,1 % briefing document, (6/2006). Disponible en: http://www.fda.gov/cder/ foi/label/2006/ 050777s012lbl.pdf. Consultado el 11 de marzo de 2007.
10. Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156: 203-21.
11. Doelker L, Tran C, Gkomouzas A, Grand D, Sorg O, Saurat JH, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1 % pimecrolimus or 0.1 % triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-6.
12. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211:174-87.
13. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264-73.
14. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer. 1997; 80:1141-50.
15. Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation. 1999;68:997-1003.
16. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl. 2000;6:253-62.
17. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1 % in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52:247-53.
18. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53Suppl2:S206-13.
19. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
20. Ellingsen AR, Sorensen FB, Larsen JO, Deleuran MS, Thestrup-Pedersen K. Stereological quantification of lymphocytes in skin biopsies from atopic dermatitis patients. Acta Derm Venereol. 2001;81:258-62.
21. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al; US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53 Suppl2:S186-94.
22. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282-9.
23. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1 % pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117:e118-28.
24. Koo JY, Fleischer AB Jr, Abramovits W, Pariser DM, McCall CO, Horn TD, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005;53Suppl2:S195- 205.
25. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204:63-8.
26. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1 % in atopic dermatitis patients. Arch Dis Child. 2003;88:969-73.
27. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144: 781-7.
28. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, et al. American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115:1249-53.
29. Harper J, Smith C, Rubins A, Green A, Jackson K, Zigure S, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005; 124:695-9.
30. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137:747-50.
31. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1 % results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003;207:37-42.
32. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006;6:270-4.
33. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005;153:701-5.
34. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808-16.
35. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818-23.
36. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol. 2005;152: 183-5.
37. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633-7.
38. Food and Drug Administration. Alerts for healthcare professionals tacrolimus (marketed as Protopic), March 2005. Disponible en: http://www.fda.gov/cder/drug/info Sheets/HCP/ProtopicHCP.htm. Consultado 11 de marzo de 2007.
39. Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Dermatolog Treat. 2005;16:149-53.
40. Food and Drug Administration. Alerts for healthcare professionals pimecrolimus (marketed as Elidel), March 2005. Disponible en: http://www.fda.gov/cder/drug/infoSheets/HCP/ elidelHCP.htm. Consultado 11 de marzo de 2007.
41. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2005;19:663-71.
42. Jiang H, Yamamoto S, Nishikawa K, Kato R. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis. 1993;14:67-71.
43. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol. 2004;149:960-7.
44. Lubbe J, Sorg O. Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol. 2004; 151:1275-6.
45. Tran C, Lubbe J, Sorg O, Doelker L, Carraux P, Antille C, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology. 2005;211:341-7.
46. Asociación Española de Pediatría. Sobre la seguridad de pimecrolimus y tacrolimus, 7 de Junio del 2005. Disponible en: http://www.aeped.es/comunicado/index.htm. Consultado 11 de marzo de 2007.
47. European Academy of Dermatology and Venereology. New recommendations of FDA and EMEA regarding labels of topical calcineurin inhibitors. Disponible en: http://www. eadv.org/article.asp?AID=421&keyword=tacrolimus. Consultado 11 de marzo de 2007.
48. American Academy of Dermatology. AAD information on Elidel and Protopic. Disponible en: http://www.aad.org/professionals/AdvocacyGovRelSkin/ tci_information.htm. Consultado el 11 de marzo de 2007.